Research programme: non-immunogenic factor VIII - Biotest AG/EpiVaxAlternative Names: Deimmunised FVIII-Tregitope
Latest Information Update: 24 Jul 2016
At a glance
- Originator Biotest AG; EpiVax
- Class Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Haemophilia
Most Recent Events
- 24 Jul 2016 Early research is ongoing in Germany and USA
- 04 Dec 2013 Early research in Haemophilia in Germany & USA (Parenteral)